148 related articles for article (PubMed ID: 38308629)
1. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy.
Giavatto C; Mourani J; Fitzpatrick C; Hardin B; Skrtic A; Evans A; Sredzinski E; Trieu S; Setter AI; Kobiska L; Lopez-Medina AI
J Manag Care Spec Pharm; 2024 Feb; 30(2):175-182. PubMed ID: 38308629
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.
Tomaszewski D
J Manag Care Spec Pharm; 2016 Aug; 22(8):919-26. PubMed ID: 27459654
[TBL] [Abstract][Full Text] [Related]
4. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
Cisek S; Choi D; Stubbings J; Bhat S
Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist biosimilar survey reveals knowledge gaps.
Stevenson JG; McCabe D; McGrath M; McBride A
J Am Pharm Assoc (2003); 2023; 63(2):529-537.e7. PubMed ID: 36437154
[TBL] [Abstract][Full Text] [Related]
6. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists' Perspectives of Biosimilars: A Systematic Review.
Mohd Sani N; Aziz Z; Panickar R; Kamarulzaman A
BioDrugs; 2022 Jul; 36(4):489-508. PubMed ID: 35776294
[TBL] [Abstract][Full Text] [Related]
8. A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners.
Foreman E; Patel H; Siderov J; Harchowal J; Bubalo J; Chan A
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):22-32. PubMed ID: 32268828
[TBL] [Abstract][Full Text] [Related]
9. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
10. Malaysian Hospital Pharmacists' Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey.
Mohd Sani N; Aziz Z; Kamarulzaman A
BioDrugs; 2023 Jan; 37(1):109-120. PubMed ID: 36571697
[TBL] [Abstract][Full Text] [Related]
11. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.
Kolbe AR; Kearsley A; Merchant L; Temkin E; Patel A; Xu J; Jessup A
BioDrugs; 2021 May; 35(3):363-372. PubMed ID: 33826078
[TBL] [Abstract][Full Text] [Related]
12. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
[TBL] [Abstract][Full Text] [Related]
13. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey.
Marín-Jiménez I; Carrascosa JM; Guigini MA; Monte-Boquet E
Farm Hosp; 2021 Jul; 45(5):240-246. PubMed ID: 34806583
[TBL] [Abstract][Full Text] [Related]
14. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
[TBL] [Abstract][Full Text] [Related]
15. Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey.
Chan A; Patel H; Siderov J; Bubalo J; Foreman E
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):11-21. PubMed ID: 32268832
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.
Pawłowska I; Pawłowski L; Krzyżaniak N; Kocić I
BioDrugs; 2019 Apr; 33(2):183-191. PubMed ID: 30830647
[TBL] [Abstract][Full Text] [Related]
17. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
Aladul MI; Fitzpatrick RW; Chapman SR
BMJ Open; 2018 Nov; 8(11):e023603. PubMed ID: 30455389
[TBL] [Abstract][Full Text] [Related]
18. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
[TBL] [Abstract][Full Text] [Related]
19. Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.
Goncalves J; Matos de Brito P; Batista A; Feio J; Machado F; Aperta J; Ascensão I; Pires V; Oliveira C; Armandina Pontes R; Alcobia A; Paulo Cruz J; Lampreia Guerreiro S; Farinha H; Margarida Freitas A; Caetano M; Almeida P; Costa B; Oliveira C; Campos C; Madureira B; Cavaco M; Catarino H;
J Clin Pharm Ther; 2017 Apr; 42(2):239-243. PubMed ID: 27859438
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
